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Abstract
Background: The discovery of novel protein biomarkers is essential in the clinical setting to
enable early disease diagnosis and increase survivability rates. To facilitate differential expression
analysis and biomarker discovery, a variety of tandem mass spectrometry (MS/MS)-based protein
profiling techniques have been developed. For achieving sensitive detection and accurate
quantitation, targeted MS screening approaches, such as multiple reaction monitoring (MRM), have
been implemented.
Methods: MCF-7 breast cancer protein cellular extracts were analyzed by 2D-strong cation
exchange (SCX)/reversed phase liquid chromatography (RPLC) separations interfaced to linear ion
trap MS detection. MS data were interpreted with the Sequest-based Bioworks software (Thermo
Electron). In-house developed Perl-scripts were used to calculate the spectral counts and the
representative fragment ions for each peptide.
Results: In this work, we report on the generation of a library of 9,677 peptides (p < 0.001),
representing ~1,572 proteins from human breast cancer cells, that can be used for MRM/MS-based
biomarker screening studies. For each protein, the library provides the number and sequence of
detectable peptides, the charge state, the spectral count, the molecular weight, the parameters that
characterize the quality of the tandem mass spectrum (p-value, DeltaM, Xcorr, DeltaCn, Sp, no. of
matching a, b, y ions in the spectrum), the retention time, and the top 10 most intense product
ions that correspond to a given peptide. Only proteins identified by at least two spectral counts
are listed. The experimental distribution of protein frequencies, as a function of molecular weight,
closely matched the theoretical distribution of proteins in the human proteome, as provided in the
SwissProt database. The amino acid sequence coverage of the identified proteins ranged from
0.04% to 98.3%. The highest-abundance proteins in the cellular extract had a molecular weight
(MW)<50,000.
Conclusion: Preliminary experiments have demonstrated that putative biomarkers, that are not
detectable by conventional data dependent MS acquisition methods in complex un-fractionated
samples, can be reliable identified with the information provided in this library. Based on the
spectral count, the quality of a tandem mass spectrum and the m/z values for a parent peptide and
its most abundant daughter ions, MRM conditions can be selected to enable the detection of target
peptides and proteins.
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Background
The identification of novel protein biomarkers for early
disease detection, risk assessment, treatment, prediction
of therapeutic response or toxicity, will dramatically
improve disease outcomes and survivability rates. The dis-
covery process of protein biomarkers relies, essentially, on
the detection and quantitation of protein differential
expression patterns in diverse samples [1-4]. Recently,
mass spectrometry has evolved into a powerful tool for
the analysis of complex proteomic extracts, and various
quantitative proteomic approaches (label-free/stable iso-
tope labeling or absolute/relative) have been developed
[5-15]. Large-scale quantitation is typically accomplished
by comparing the sample of interest to a pre-defined ref-
erence sample of similar complexity. The classical data-
dependent driven MS/MS profiling technique, in which
an attempt is made to detect all components in a pro-
teome, has provided limited reproducibility for quantita-
tion purposes and limited capability for detecting low
abundant proteins, such as the case of many biomarkers.
At the cost of restricting the discovery potential, a targeted
screening approach, i.e., multiple reaction monitoring,
has been developed to enable the reliable detection and
quantitation of representative peptides for selected pro-
teins. While MRM is one of the most sensitive MS scan-
ning modes for peptide identifications, it is best
applicable to previously identified peptides with known
MS/MS fragmentation pattern [16,17]. An MRM experi-
ment is conducted by selecting representative peptides of
a protein with known m/z values (precursor ions), frag-
menting them through collision induced dissociation
(CID), and monitoring only specific, pre-selected daugh-
ter fragments (product ions) that are characteristic to each
precursor. The combination of a precursor-product m/z
values is known as a 'transition,' and is highly specific for
a given peptide amino acid sequence. As only a narrow
mass range around the m/z of the daughter ion is moni-
tored by MS, the method provides for a fast and sensitive
detection of selected peptides. When combined with
methods that rely on the use of stable isotope-labeled
peptide standards, this approach can be successfully
applied for the absolute and relative quantitation of low
abundant components in complex samples. With this
method, 47 high/intermediate-abundance proteins were
quantified successfully in human plasma (<1 μg/mL level,
coefficient of variation, CV = 2–22%) [18], and C-reactive
protein [19], human growth hormone [20], and prostate-
specific antigen [21] were measured in plasma or serum.
Alternatively, MRM-based approaches have been used to
identify the presence of phosphorylation on key cell cycle
regulatory proteins [22], to quantify multisite phosphor-
ylation [23], and to perform quantitative proteomic anal-
ysis of cellular signaling networks [24].
In most MS quantitative studies, the instrument of choice
is a triple quadrupole mass spectrometer. Recently, a new
type of MS instrument, i.e., the linear ion trap, has gained
popularity among proteomics researchers. In a triple
quadrupole instrument, CID is accomplished by acceler-
ating the precursor ions in a dc/rf electrical field to induce
fragmentation through successive collisions with back-
ground gas molecules (multi-step fragmentation). In an
ion trap instrument, CID is accomplished by exciting the
precursor ions at their resonant frequency. As the product
ions have different masses than the precursor ion, they are
not in resonance with the excitation frequency, and are
not subjected to further ion fragmentation as in a triple
quadrupole instrument (single-step fragmentation). Thus,
the analysis of large peptides by MRM in linear ion-trap
mass spectrometers can be performed with improved
detection limits, due to the formation of fewer but more
intense product ions in the ion trap vs. the triple quadru-
pole [25,26]. By using one-dimensional chromatographic
separations and linear ion trap MS detection, the quanti-
tation of 5 intermediate-abundance serum proteins by
MRM, with good precision and accuracy, at ~1–30 μg/mL
levels, was reported [27].
In order to perform MRM experiments, the m/z of a spe-
cific peptide precursor and its selected product ions must
be known. Large-scale proteomic analyses on various
mass spectrometry platforms have revealed that proteins
are consistently identified by only a handful of possible
tryptic peptides, and that frequently observed peptides are
not necessarily generated from the most abundant pro-
teins. The peptides that are preferentially observed for a
protein are called "proteotypic" [28-30]. For example,
Mallick et al. have classified a peptide as being proteotypic
if it was observed in >50% of all identifications of a corre-
sponding protein (based on data obtained from large
yeast proteomic archives), and evaluated 494 numeric
physicochemical property scales for amino acids (e.g.,
charge, secondary structure, hydrophobicity, etc.) to
develop a computational tool that can predict the proteo-
typic propensity of a peptide [28]. In addition, machine-
learning algorithms have been developed to generate
information related to the peptide fragmentation pattern
[31]. Nevertheless, such computational predictions are
often mass spectrometry platform dependent. Tandem
mass spectra of proteotypic peptides, most commonly
generated on quadrupole or 3D ion trap instruments,
have been collected so far in databases such as PeptideAt-
las [32], GPM [33] and PRIDE [34]. Due to differences in
the CID process, as discussed earlier, triple quadrupoles
and ion traps often generate different peptide fragmenta-
tion patterns (i.e., different product ion species with dif-
ferent intensities), and to date, very few data generated by
linear ion trap instruments have been made available
through public repositories. In this work, we provide
human breast cancer tandem mass spectrometry data gen-
erated on a linear ion trap instrument (LTQ/Thermo) that
were collected into a library of 1,572 proteins matched byBMC Cancer 2009, 9:96 http://www.biomedcentral.com/1471-2407/9/96
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a list of 9,677 peptides. Among many parameters, the
spectral count for each ion species, the best p-value, and
the top 10 most intense daughter ions are provided to
enable the selection of the most frequently identified pep-
tides for MRM proteomic explorations. Validation of pro-
tein identifications, and relative/absolute protein
quantitation for biomarker discovery or screening, are
envisioned to be the most relevant applications that
would benefit from the information provided in this
table.
Methods
Cell culture and processing
MCF-7 cells were cultured in EMEM with 10 μg/mL
bovine insulin and 10% FBS, in an incubator maintained
at 37°C with 5% CO2 [35]. At 70% confluence the cells
were harvested, rinsed three times with phosphate buffer
saline (PBS), and lysed by rocking at 4°C (2 h) with a lysis
solution prepared from 1 mL RIPA buffer (500 mM
TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxy-
cholic acid, 10 mM EDTA), 100 μL protease inhibitor
cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leu-
peptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-
64), phosphatase inhibitors [100 μL NaF (~100 mM) and
50 μL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.
After centrifugation at 13,000 rpm and 4°C (15 min), the
supernatant was collected and its protein concentration
was measured by using the Bradford assay performed at
595 nm with a SmartSpec Plus Spectrophotometer (Bio-
Rad, Hercules, CA, USA). Protein digestion was performed
by first treating the protein extract with urea (8 M) and
DTT (4.5 mM) at 60°C (1 h) to denature the proteins and
cleave the disulfide bonds, followed by 10× dilution with
50 mM NH4HCO3 and trypsinization at 37°C for 24 h
(50:1 w/w protein:enzyme ratio). The protein digest was
desalted with SPEC-PTC18 solid phase extraction pipette
tips (Varian Inc., Lake Forest, CA, USA), concentrated to
~4 mg/mL, and stored at -80°C prior to further analysis.
SCX-LC-MS/MS
SCX-LC-MS/MS analysis was performed with a micro liq-
uid chromatography system (Agilent Technologies, Palo
Alto, CA, USA) interfaced to an LTQ ion trap mass spec-
trometer (Thermo Electron Corp., San Jose, CA, USA). The
protein digest was prefractionated into 16 sample sub-
fractions using a Zorbax Bio SCX Series II column (0.8
mm i.d. × 5 cm) from Agilent Technologies. Solvent A was
H2O/CH3CN (95:5 v/v) supplemented with 0.1%
HCOOH, and solvent B was H2O/CH3CN (95:5 v/v) sup-
plemented with 0.1% HCOOH and 500 mM NaCl. The
eluent gradient ran from 0 to 100% B (50 min) at a flow
rate of 20 μL/min. Each SCX sub-fraction was analyzed by
RPLC-MS/MS. Reversed phase columns were prepared in-
house from fused silica capillaries [100 μm i.d. × (8–12
cm) long] packed with 5 μm Zorbax SB-C18 particles (Agi-
lent Technologies), and connected to 1 cm long (20 μm
i.d. × 90 μm o.d.) nanospray emitters to enable electro-
spray ionization (ESI)-MS analysis. The ESI voltage was
2,000 V. Solvent A was H2O/CH3CN (95:5 v/v) and sol-
vent B was H2O/CH3CN (20:80 v/v), both supplemented
with 0.01% trifluoroacetic acid (TFA). The split flow rate
through the HPLC column was ~160–180 nL/min. The
eluent gradient was from 10 to 100% B, the gradient
length being 80–215 min long. Three sets of SCX samples
(48 sample sub-fractions) were subjected to LC-MS/MS
analysis (total sample analyzed estimated to be ~15–42
μg per set). Alternatively, ten MCF-7 protein extract
digests were cleaned up with SPEC-PTC18 and SPEC-
PTSCX cartridges, and analyzed directly by LC-MS/MS
without prior SCX fractionation. As the sample amount
subjected to analysis was different for every SCX set, the
length of the μLC columns and the LC gradients varied
from one set of analyses to another.
Tandem MS data analysis
Data dependent MS analysis was performed by acquiring
one MS scan (5 microscans averaged) followed by one
zoom scan (5 microscans averaged) and one MS2 on the
top 5 most intense peaks. The zoom scan width was ± 5
m/z, and the dynamic exclusion was enabled at repeat
count 1, exclusion list size 200, exclusion duration 60 s,
and exclusion mass width ± 1.5 m/z. Collision induced
dissociation was performed by setting the ion isolation
width at 3 m/z, normalized collision energy at 35%, acti-
vation Q at 0.25, and activation time at 30 ms. The com-
bined results of 48 SCX-LC-MS/MS and 10 LC-MS/MS
runs were used to perform protein database searching.
Protein identification was performed with the Bioworks
3.3 software (Thermo Electron Corp, San Jose, CA, USA)
by using a minimally redundant database downloaded
from SwissProt (37,678 entries) on January 2008. The
database search parameters were chosen as follows: only
fully tryptic fragments were considered in the analysis, the
number of allowed missed cleavage sites was 2, the pep-
tide tolerance was 2 amu, and the fragment ion tolerance
was 1 amu. Chemical and/or posttranslational modifica-
tions were not allowed. The capability to match one pep-
tide sequence to multiple protein references within the
database was not enabled. MRM data acquisition was per-
formed using the same CID parameter settings as for data
dependent analysis, and included the development of LC-
MS/MS runs with 1–6 segments (20–240 min long) and
6–9 scan events/segment. Specific conditions for each
transition are discussed in the following sections of the
manuscript.
Reagents
MCF-7 cells and cell culturing reagents [Eagle's Minimum
Essential Medium (EMEM), fetal bovine serum (FBS),
insulin, trypsin/EDTA for cell detachment] were pur-
chased from ATCC (Manassas, VA USA). RIPA lysis buffer
was obtained from Upstate (Lake Placid, NY, USA). Pro-BMC Cancer 2009, 9:96 http://www.biomedcentral.com/1471-2407/9/96
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tease inhibitor cocktail, phosphatase inhibitors, NaCl,
TFA, HCOOH, TrisHCL, urea and DTT were purchased
from Sigma (St. Louis, MO, USA). Sequencing grade mod-
ified trypsin was from Promega Corp. (Madison, WI,
USA). NH4HCO3 was purchased from Aldrich (Milwau-
kee, WI, USA). HPLC grade acetonitrile was purchased
from Fisher Scientific (Fair Lawn, NJ, USA), and deionized
water (18 MΩ -cm) was generated using a MilliQ
ultrapure water system (Millipore, Bedford, MA, USA).
Results and discussion
Library construction and content
Large scale proteomic studies on MCF-7 and/or other
breast cancer cell lines have resulted in the combined
identification of ~1,000–4,000 proteins by using 2D-gel
electrophoresis or shotgun analysis protocols (false posi-
tive rates of <5%) [35-38]. In this work, a protein/peptide
library was generated from 58 LC-MS/MS data dependent
analyses (see Additional file 1: Appendix 1). Tandem MS
data were filtered at the peptide level with the Xcorr vs.
charge state filter set at Xcorr = 1.5 for z = 1, Xcorr = 2.0 for
z = 2, and Xcorr = 3.0 for z ≥ 3, respectively, and at the pro-
tein level by considering only proteins with ≥ 2 spectral
counts. A total of 2,286 proteins (p < 0.001) were identi-
fied. The library comprises 1,572 proteins (all with ≥ 2
spectral counts) matched by 9,677 peptides (all with p <
0.001, p being the probability of a random match as cal-
culated by the Bioworks software). By using such MS data
filtering parameters and by selecting only proteins and
peptides with p < 0.001, the rate of false positive identifi-
cations [39] when searching the data against a forward/
reversed human protein database was ~1.5% and ~4.5%
at the peptide and protein levels, respectively. At the pro-
tein level, the library provides the p-value, the score, the
sequence coverage, the molecular weight, and the number
of total and unique peptides observed for each protein.
The total number of observed peptides (or the peptide
hits) represents the spectral count. In addition, based on
the protein sequences provided in the SwissProt database,
we calculated the theoretically observable peptides, i.e.,
the tryptic peptides with maximum 2 missed cleavages
(we note that the raw data were searched against the
human database by allowing for such peptides in the
search). The ratio of the unique observed to observable
peptides is an indicative of the protein abundance, and
was previously coined as the protein abundance index-
PAI [40,41]. At the peptide level, the library provides the
amino acid sequence of each peptide, the charge state, the
spectral count of each peptide at each identifiable charge
state, the protonated mass (MH+), the parameters that
characterize the quality of a tandem mass spectrum [Del-
taM, p-value, Xcorr, DeltaCn, Sp, the # of matching ions
(b, y and a) in the tandem mass spectrum], the retention
time of the peptide, the length of the LC gradient (10 to
100% B), and 10 product ions from each tandem mass
spectrum for MRM analysis. As every peptide sequence
generated several tandem mass spectra, the data from
Appendix 1 (see Additional file 1) correspond to the spec-
tra with the best (i.e., the lowest) p-value. Four in-house
developed Perl-scripts were used to generate the library.
The first Perl-script was used to calculate the spectral
count (from all 58 LC-MS/MS experiments) for each
unique amino acid sequence peptide at a given charge
state, and to select the best tandem mass spectrum for this
peptide (i.e., the mass spectrum with the lowest p-value).
A second Perl-script was used to select representative ions
for MRM analysis. The strategy involved the extraction of
the top 10 most intense daughter ions from the DTA file
associated with the best tandem mass spectrum of a pep-
tide. Ions in the vicinity of the parent (m/zparent ± 60) were
excluded to avoid the selection of adducts or neutral loss
ions. In addition, ions in the immediate vicinity of a frag-
ment (m/zfragment ± 3) that was already selected for MRM
were excluded, as well, to avoid duplication by the selec-
tion of isotopic peaks. The third Perl-script was used to
calculate the observable peptides for each protein. The
algorithm involved performing in-silico tryptic digestion
for each protein in the SwissProt database, and counting
the number of peptides with mass ranging from 500 to
4,000 Da and with 0, 1 or 2 missed cleavages. The fourth
Perl-script was used to extract the LC retention time of
each peptide from the Sequest result files.
Data evaluation
To obtain a qualitative view of how well this protein pool
represented the human proteome, a chart reflecting the
experimental frequency of the 1,572 identified proteins as
a function of MW (that ranged from ~5,000 to ~1,000,000
Da) was constructed, and compared to a similar chart
reflecting the theoretical protein distribution downloaded
from the SwissProt/Expasy website http://www.expasy.ch
(see Figure 1). The MW was expressed in terms of number
of amino acids per protein, by assigning to each amino
acid the molecular weight of averagine (i.e., MW =
111.12) [42]. The experimental and theoretical distribu-
tions were fairly similar, illustrating that our dataset com-
prised a representative set of proteins, and that our
experimental protocol performed well in sampling the
human proteome. A small bias towards proteins with a
larger number of amino acids, was, however, observed. It
was noticed that proteins with a sequence shorter than
200 amino acids (MW~22,200) were less frequently
encountered. The theoretical and experimental protein
distributions peaked at proteins containing 140–160 and
180–200 amino acids, respectively. Similar results were
obtained if all proteins with p < 0.001, not just the ones
with two spectral counts, were considered in the compar-
ison. Assuming that there was no bias introduced by los-
ing peptides belonging to small MW proteins during
sample processing (e.g., by protein digestion, recovery of
peptides from clean-up cartridges, etc.), we attributed this
bias to a lower sampling rate during MS data dependentBMC Cancer 2009, 9:96 http://www.biomedcentral.com/1471-2407/9/96
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analysis, as a result of a smaller number of matching tryp-
tic peptides that can be generated from low MW proteins.
We would expect that large MW proteins will generate a
larger number of peptides, increasing, thus, the likelihood
of detection during a data dependent analysis process. For
this data set (1,572 proteins), the increase in observable
(theoretical) tryptic peptides with the protein MW is
shown in Figure 2A, and the ratio of experimental percent-
age of identified proteins to the theoretical percentage
(according to the SwissProt chart) vs. the number of
amino acids in a protein, is shown in Figure 2B. The range
of 20–1,940 amino acids/protein corresponds to a range
of MW of 2,222<MW<215,573. Low MW proteins are
clearly under-sampled in our extract, and the number of
available peptides/protein for MS detection could provide
at least a partial explanation for a more successful map-
ping, in terms of numbers, of high MW proteins. How-
ever, the dynamics of protein turnover is an additional
factor that may affect the success of MS detection in com-
plex cellular extracts. Effective sampling of a proteome, in
a relevant biological context, will have to take into
account correlations between protein function, protein
half-live (that can vary from minutes to hours or days),
and eventually protein MW.
Protein detectability is not only dependent on the number
of observable peptides/protein, but also on the protein
abundance and the proteotypic propensity of the match-
ing peptides, and can be assessed in terms of sequence
coverage. For this data set, we note that while the overall
sequence coverage of the identified proteins was fairly
broad (i.e., 0.04%–98.3%), the low MW proteins were
clearly indentified with a higher sequence coverage
despite the smaller number of unique peptides/protein
(Figure 3A). The observed number of unique or total pep-
tide hits (spectral counts), while dependent on the protein
MW, is also a strong indicative of the protein abundance
and of the peptide propensity for MS identification. This
quantitative relationship is represented in Figure 3B for
unique peptides, and in Figure 3C for total spectral
counts. To eliminate the bias introduced by high MW pro-
teins generating more peptides, Figure 3B displays the
Proteomic maps Figure 1
Proteomic maps. (A) Theoretical distribution of the 
human proteins according to the SwissProt database 
(~25,000 genes); (B) Experimental distribution of the 1,572 
proteins from the MCF-7 library (all proteins were identified 
with p < 0.001 and ≥ 2 spectral counts).
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Charts that illustrate the impact of protein size on likelihood  of detection Figure 2
Charts that illustrate the impact of protein size on 
likelihood of detection. (A) Chart illustrating the distribu-
tion of observable (theoretical) tryptic peptides as a function 
of protein MW, for the set of 1,572 proteins; (B) Chart illus-
trating the ratio of the experimental percentage of identified 
proteins to the theoretical percentage of proteins vs. the 
number of amino acids in a protein. The experimental pro-
tein percentages were calculated relative to the total number 
of identified proteins, and the theoretical percentages were 
calculated relative to the total number of proteins in the 
SwissProt database.
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ratio of the experimentally observed unique peptides to
the theoretically observable peptides as a function of pro-
tein MW. Proteins with MW<50,000 were found to be
more abundant in the cellular extract, the most abundant
proteins peaking out at MW~20,000–30,000. We must
note, however, that many experimental factors can affect
the interpretation of results. For example, the extraction,
denaturation and tryptic digestion of proteins could cor-
relate negatively with the MW of proteins, resulting, thus,
in a lower number of observed peptides/protein. We
should also note that peptides with propensity for identi-
fication will generate progressively increased spectral
counts at higher abundance levels, as they elute as broader
chromatographic peaks during LC-MS/MS analysis. The
chart that is displayed in Figure 3C eliminates the impact
of peptide propensity for detection by providing the
number of spectral counts/number of experimentally
detected unique peptides as a function of protein MW,
and strengthens the conclusion that proteins with
MW<50,000 were, overall, more abundant (assuming that
the MW of the originating proteins introduced no consist-
ent bias in the proteotypic behavior of peptides). Further
work will be, however, necessary to evaluate the impact of
protein size, hydrophobic properties and packing on the
effectiveness with which large MW proteins are processed
and detected experimentally, to enable more general con-
clusions regarding the abundance of proteins in whole
cellular extracts.
MRM analysis
The information provided in the protein/peptide library
can be effectively used to perform MRM experiments. The
spectral count of each peptide, at the detectable charge
state, reflects its propensity for identification (we note that
not all peptides with high spectral count are necessarily
proteotypic according to the definition provided in refer-
ence 28, i.e., that are detectable in >50% of the trials that
identified the corresponding protein). The p-value and
the other SEQUEST scores reflect the quality of the tan-
dem mass spectrum that led to the identification of the
peptide. Up to ten MRM transitions can be set up for each
parent ion. By displaying only peptides with p < 0.001
[i.e., -10log(p)>30], it was ensured that the ions selected
by the Perl script were mostly a, b, y, H2O/NH3-neutral
loss or multiple loss ions, but not noise or other contam-
inants. We note, however, that the experimental product
ions were generated by enabling the database search with
a fragment ion tolerance of 1 amu, thus contaminant
product ions within this mass window are possible. Quick
manual corroboration with software packages such as
Protein Prospector http://prospector.ucsf.edu can confirm
the validity of the product ions in the library, and help
eliminate contaminant ions that do not belong to the con-
sidered peptide. Generally, the lower it is the p-value of a
peptide [i.e., the higher the -10log(p)], the less likely it is
the presence of extraneous fragment ions in the list.
The applicability of this peptide library for the identifica-
tion of putative biomarkers in proteomic samples is dem-
onstrated with a few examples that involved the analysis
of un-fractionated MCF-7 protein extracts. Whole cellular
extracts represent a good testing system for demonstrating
the effectiveness of MRM analysis, as due to complexity,
the extracts do not facilitate the detection of low abun-
dance components. When using a data dependent acqui-
sition process, such extracts typically enabled the
Charts that illustrate protein abundance as a function of pro- tein MW, for the set 1,572 proteins Figure 3
Charts that illustrate protein abundance as a func-
tion of protein MW, for the set 1,572 proteins. (A) 
Chart illustrating protein abundance as a function of MW in 
terms of experimental protein sequence coverage; (B) Chart 
illustrating protein abundance as a function of MW in terms 
of observed/observable unique peptides; (C) Chart illustrat-
ing protein abundance as a function of MW in terms of spec-
tral counts/observed unique peptides.
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Table 1: MRM transition chart for the identification of putative protein biomarkers.
Protein/Peptides z -10lg(p) Spectral count MRM range (min) Transitions (MH+ → product ions)
O43399|TPD54_Human Tumor Protein D54
GLLSDSMTDVPVDTGVAAR 2 91 2 40-90 952.47→
(885.3, 1019.2, 1200.3, 1099.2, 574.3)
VVGDRENGSDNLPSSAGSGDKPLSDPAPF 
(no ID)
3 136 15 0-240 962.45→
(1312.0, 1228.1, 1127.0, 1256.3, 815.9)
LGLSTLGELKQNLSR (no ID) 2 114 5 0-240 814.97→
(1044.3, 617.3, 745.3, 673.4, 1157.4)
TPAVEGLTEAEEEELRAELTKVEEEIVTLR 3 300 8 145-170 1128.58→
(1508.1, 1443.7, 1358.6, 1063.0, 1244.1)
P31947|1433S_Human 14-3-3 protein sigma
LAEQAERYEDMAAFMK 2 112 4 40-90 951.94→
(1205.2, 698.1, 1478.2, 795.4, 1625.2)
VLSSIEQKSNEEGSEEKGPEVR (no ID) 3 133 9 0-240 811.06→
(740.6, 1110.0, 966.5, 1080.0, 557.2)
P27797|CALR_Human Calreticulin precursor
SGTIFDNFLITNDEAYAEEFGNETWGVTK 3 300 25 125-145 1090.16→
(1512.0, 1424.0, 1462.1, 991.2,1289.7)
FYGDEEKDKGLQTSQDAR 2 141 13 0-40 1043.98→
(1841.9, 803.6, 975.5, 1112.6, 1104.6)
IDNSQVESGSLEDDWDFLPPKK 3 85 14 0-240 840.40→
(981.9, 1146.5, 932.8, 1089.3, 1204.0)
P08195|4F2_Human 4F2 cell-surface antigen heavy chain
ADLLLSTQPGREEGSPLELER 3 84 5 40-90 770.73→
(706.2, 893.3, 900.6, 842.4, 1004.3)
IKVAEDEAEAAAAAK 2 94 5 0-240 743.89→
(1245.2, 1146.1, 946.1, 831.1, 1075.1)
P07339|CATD_Human Cathepsin D precursor
ISVNNVLPVFDNLMQQK 2 119 22 90-125 980.02→
(1219.3, 1332.3, 880.5, 610.1, 724.2)
LVDQNIFSFYLSRDPDAQPGGELMLGGTD
SK
3 300 23 0-240 1124.21→
(1261.3, 1344.6, 1055.2, 1016.1, 1579.6)
P46013|Ki-67 antigen (no ID)
AQALEDLAGFKELFQTPGHTEELVAAGK 
(no ID)
3 71 1 0-240 990.84→
(1208.4, 1080.1, 604.9, 1386.6, 924.7)
SGGSGHAVAEPASPEQELDQNKGK (no 
ID)
3 44 1 0-240 798.38→(956.0,870.9, 643,2, 921.0, 653.1)BMC Cancer 2009, 9:96 http://www.biomedcentral.com/1471-2407/9/96
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identification of only ~400–600 proteins with p < 0.001
(~200–300 proteins with 2 spectral counts) per LC-MS/
MS run, i.e., ~5 times less than the SCX prefractionated
samples that enabled the identification of ~2,000 proteins
[35]. The following scenarios were encountered during
data dependent analysis of a whole cellular extract: (1) the
protein and all matching peptides from the library were
identifiable; (2) the protein was identifiable by some, but
not all matching peptides from the library; and (3) the
protein was not identifiable by any of the peptides listed
in the library. The detection of a set of seven putative
biomarker proteins, as previously reported in the litera-
ture [43-45], was facilitated by enabling MRM transitions
for the corresponding peptides that are shown in Table 1.
The proteins and the peptides that were not detectable in
the whole extract by data dependent analysis are marked
with "no ID." Peptides from the library with the largest
number of spectral counts and best SEQUEST scores
(most importantly with the lowest p-values) were selected
for MRM analysis. The product ions that were monitored
for these peptides were the first five most intense. Repre-
sentative results of extracted ion chromatograms (EIC) for
these transitions are summarized in Figure 4. As the LTQ
is a relatively low mass accuracy/resolution instrument,
the mass window that was monitored around a product
ion in the EIC was fairly broad (m/z = ± 1.5), enabling,
thus, contaminant fragments to interfere with the MRM
analysis. However, the ability to detect all transitions at
the retention time of the parent peptide can greatly
increase the specificity of detection, as contaminants with
the same precursor m/z, same fragment(s) m/z, and same
retention time, are highly unlikely.
When a protein was detectable in the whole cell extract by
data dependent analysis, very strong product ion peaks
were observable in the EIC of each transition that was ena-
bled for a peptide (see Figure 4A, peptide at 139.58 min).
In Figure 4A, each transition was enabled for 20 min. Nev-
ertheless, such transitions can be enabled for a much
shorter time, when the retention time (tr) of a peptide is
well controlled, or for longer times, or even for the entire
length of the experiment, when the tr is not known. Given
that the LC-MS/MS analyses that contributed with data to
this library were conducted for different lengths of time,
the peptide tr(s) in Figure 4 do not correspond to the tr(s)
from the library. To enable a rough prediction of a peptide
tr, the length of each LC gradient (10–100% B) is also pro-
vided. We note that (a) both retention time and gradient
length include a ~20 min dead-time corresponding to the
elution of non-retained components from the LC column,
and (b) the gradient was not linear, as 80–90% of the gra-
dient length was dedicated to increase the % B from 10 to
45%. Later experiments in our lab have confirmed that
retention time/gradient length estimates could be obtained
within ± 10–25% of the values provided in the library.
The presence of contaminant peptide species with close
m/z to the peptide of interest, and with several overlap-
ping transitions, was observed in our MRM studies (see
Figure 4B, monitored peptide at 72.77 min, contaminant
peptide at 41.06 min). Interference from such peptides
can be eliminated by narrowing the m/z window that is
used for the generation of the EIC, or by narrowing the
time window that is used for monitoring the MRM transi-
tion (when the elution time of the peptide is known). For
example, if the MRM transitions would have been enabled
only from 70 min to 75 min, the contaminant peptide at
41.06 min would have not interfered with the analysis.
In cases when the protein was not detectable in the whole
extract by data dependent analysis (such as the case of Ki-
67 and PCNA proteins), many of the matching peptides
P12004|PCNA_HUMAN Proliferating cell nuclear antigen (no ID)
ATPLSSTVTLSMSADVPLVVEYK (no ID) 2 106 4 0-240 1204.63→
(847.2, 1561.2, 1061.2, 1437.3, 538.1)
FSASGELGNGNIK (no ID) 2 98 7 0-240 647.32→(716.1, 744.2, 546.1, 902.2, 989.2)
LSQTSNVDKEEEAVTIEMNEPVQLTFALR 
(no ID)
3 101 5 0-240 1097.88→
(1559.1, 1551.3, 1393.6, 1467.1, 937.4)
YYLAPKIEDEEGS (no ID) 2 112 8 0-240 757.35→(1003.5, 676.4, 511.2, 1074.5, 
1187.6)
DLSHIGDAVVISCAK (no ID) 2 113 4 0-240 764.39→(962.2, 566.1, 606.9, 650.4, 
1075.2)
NLAMGVNLTSMSK (no ID) 2 35 5 0-240 683.34→(503.2, 864.1, 1064.1, 1067.3, 
936.2)
Peptides or proteins marked with "no ID" were not detectable in the whole protein extract by data dependent MS analysis. Transitions that did not 
result in peptide identification in the EIC are marked in bold.
Table 1: MRM transition chart for the identification of putative protein biomarkers. (Continued)BMC Cancer 2009, 9:96 http://www.biomedcentral.com/1471-2407/9/96
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were still detectable by most, if not all, MRM transitions
(see Figure 4C, peptide at 157.43 min). Figure 4C presents
the case of a Ki-67 peptide for which MRM transitions
were enabled for the entire length of the LC-MS/MS exper-
iment. Even in the presence of contaminating transitions,
the identification of the peptide could be confirmed by
the detection of all predicted transitions at the expected tr.
For other peptides, certain transitions were not observable
in the EIC. Such transitions are shown in bold in Table 1.
Missed transitions were especially observable in the case
of library peptides identified by only one spectral count
and p-values that were just above the threshold set for
elimination from the list. For example, in the case of
PCNA, the identification of peptide NLAMGVNLTSMSK
was not conclusive based on the transitions that were pro-
vided in the library (Figure 4D), i.e., consistent transitions
at the predicted peptide tr were not observable. Cross val-
idation with Protein Prospector revealed that the first
three transitions were probably not even correct for this
peptide. The protein was, however, identifiable by MRM
transitions enabled for other matching peptides.
Conclusion
In summary, through this work, we make available for pub-
lic use tandem MS information generated for a list of 1,572
proteins from MCF-7 human breast cancer cells. Unlike
publically available empirical databases, our library pro-
vides a large set of proteins and peptides that can be identi-
fied in human cancerous cells under a consistent set of
experimental conditions. As the data were generated with a
linear ion trap mass spectrometer, the library strategically
complements existing information generated with ESI-
Extracted ion chromatograms illustrating five MRM transitions/peptide for the identification of putative cancer biomarkers in  whole cellular extracts Figure 4
Extracted ion chromatograms illustrating five MRM transitions/peptide for the identification of putative can-
cer biomarkers in whole cellular extracts. Conditions: MCF-7 whole cellular extracts were digested with trypsin, 
cleaned-up with SPEC-PTSCX and SPEC-PTC18 cartridges, and analyzed by a ~4 h long LC-MS/MS gradient. The top-down 
order of EICs reflects the order of the five transitions shown in Table 1.
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quadrupole (Q), ESI-Q-time-of-flight (TOF), ESI-ion cyclo-
tron resonance (ICR) or matrix assisted laser desorption
ionization (MALDI)-TOF instruments. Moreover, the avail-
ability of spectral count data provides information related
to the abundance and proteotypic propensity of peptides,
at given charge states, in the context of complex cellular
extracts. The library enables the development of MRM-MS
protocols for the identification of possibly hundreds of tar-
get proteins with particular relevance to biomarker screen-
ing and discovery applications. Key for the identification of
a set of protein biomarkers in a complex un-fractionated
cellular extract will be the development of MRM strategies
that involve the selection of several peptides/protein (pos-
sibly with the highest spectral count and best SEQUEST
scores) and of multiple transitions/peptide. Custom-pre-
pared isotopically labeled versions of selected peptides
could be further used for performing quantitation studies.
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